Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors)
At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors). The Reimbursement Committee recommends that losartan-containing medicines1 be granted general unconditional reimbursement and that the remaining medicines no longer be eligible for general reimbursement.
The Reimbursement Committee's recommendation of 29 March 2010 is available in the factbox to the right (in Danish only).
On 30 March 2010, the Danish Medicines Agency initiated a consultation of the companies whose medicinal products are comprised by the Committee's recommendations. A copy of the Danish Medicines Agency's letter can be seen in the factbox to the right (in Danish only).
The consultation is open until 7 May 2010.
Moreover, we have sent a notification about the Reimbursement Committee's recommendation to the Danish Society of Cardiology, Danish Endocrine Society, Danish Hypertension Society, Danish Society for Vascular Surgery, Danish Surgical Society, Danish Medical Society, Danish Society of Nephrology, Danish Paediatric Society, Danish College of General Practitioners, Danish Stroke Society, Danish Society of Geriatrics, Danish Society of Internal Medicine, Danish Society of Clinical Pharmacology and Danish Society of Obstetrics and Gynaecology. In addition, the National Board of Health and the Institute for Rational Pharmacotherapy have been briefed.
For further information, please contact the Reimbursement Department, email@example.com.
1 With very few exceptions, which are further described in the Reimbursement Committee's recommendation.
Danish Medicines Agency, 31 March 2010